Member Info for potnak

SOG posted a couple of times!

Smart. My hunch is they did know or at least had an idea that it was coming and that the Edison interview was damage limitation. I said, they looked awkward, JR was keen to say good toxicology data. I think the interview was a nod to say we think it's OK but we are going into 2026. Somewhat ironically, after everything that has been written here, the CNS path could now be the thing they can legitimately talk about whilst 1801 data is looked at.

Warty, if, big ID, I know but if 737 is a goer it's worth £300 million on its own.

Personally I'd vote against anything that doesn't give us at least all time highs. £1.76 I think. I'd rather lose than sell for less. I'm not saying one will come just that, when the shareholders are reeling, is a good time to pounce.

If I was watching sareum. Now would be the time I'd make the offer. Parker needs to give the shareholders some confidence that 1801 is good and they need to do it soon.

I've no idea of value now because there is a big question mark hanging over 1801 and possibly the TYK2 compound as a whole but if an official offer is made. The board must notify the shareholders who, IMO, are spooked enough to accept. If the questions around 1801 safety are answered then it put Sareum back in the driving seat.

Looks to have held just under 16p. Let's see if any delayed trades comes in. I said earlier. I think this opens up SAR to potential TO offers. So risky to in and out at the moment.

Both groups identical delivery methods. Treatment group given 1801 compound. Control group was given an inactive dose. We will need to wait and see what the data says. Could become of many things. It might even be Sareum's viagra moment. A lab wide infection that didn't affect the those dosed on 1801. Theat could be fun.

Wish you well, Baton. Ironic, the times you called me negative though. I'm probably still blocked.

Agreed, Ben. But elcap was saying thatvwas now safe and, frankly, we just don't know that without running the whole study again. The issue will more than likely be the delivery method. The method needs to be identical in both groups. The data might even show that an immune response to the dosing in the treatment group made the patients less likely to be affected by the safety concerns. This happen a lot in cancer trials. Where the tumour growth speeds up in the control group. We need to wait and see.

Not sure I read it like that, elcap. The RNS said "the findings observed during the study were disproportionately present in control-group animals which were not treated with SDC-1801". This, for me, says there were still findings in the treatment group. However, it doesn't say what the findings were. We are not out of the woods, and that why the drop. Hopefully, they've I'll find out the cause quickly and we can get back to excitedly waiting rather than anxious waiting.

They can't buy until final results are published.

Matty, the reason I think this, is SAR aren't equipped, resource wise or financially to just ride over this. If SAR have been in talks with a bigger phama, then a low offer might be tabled. The shareholders, now spooked would probably take it too. However, If SAR can prove it wasn't 1801 then IMO, £500 million should still be the minimum for the lot.

Hopefully, the board can release a positive update for 1801 in the final results report. I'm hoping the IM call can be focused more on strategic plans going forward so we don't get bogged down with the blame game. They need to come out fighting and give us milestones and timescales that can be met. If they can derisk the setback and push the the threat of a fund raise into next year, we will be back on track. Albeit, with another wait in store.

The big sells may yet turn out to be warrants. We'll get a RNS when all transacted. Imagine selling half a million shares this week for 20p and above and then buying back in below from 10p up.

If they can review the data and give us a positive update. Then this is just another bump in the road tgat SAR always seem to find. Maybe they should have done this study in Australia as per the 1a trial. Somewhat ironically, I think this little setback, make sareum a a low ball TO target.

Westcountry. It move up too fast to buy at 10p. I was out on the wilds with my dog when I read the RNS. Bought as soon as I could.

Well, to go against what some here think of of me. I just bought £4 k worth at 13p. Bargain.

I just think they are nieve, nicely. I genuinely believe they thought they were going to create a buzz around a new compound. There may have been a secondary aim to gently push timescales into 2026 but IMO, if there was an issue with the tox study. They wouldn't be now pursuing another TYK2 indication using a similar molecular makeup? Unless it isn't similar? The ability to not sticking to your own deadlines always blows my mind. Why set them if you can't deliver on time? The AGM statement, last year said tox study to complete by mid 2025. In reality, it was only 'initiated' in May 2025, what ever that means. JR is on record saying minimum 6 months. TM said 16 weeks plus a month's. But as we don't know the exact start date, we can't be sure if the deadline has even been missed yet. It's deliberate obfuscation from the board. My only real gripe is the new CNS work has presumably taken up much needed funds from a dwindling pot and that might result in a placing and or other dilluting finance. If the board had met the mid 2025 deadline, they set. We might have had a licence by now.

If we are to get any meaningful update on 1801, there will need to be an RNS between now and the 23rd Oct. I hope the accountants amongst us will be able to review the cash spend and reserves in time for the presentation. We just need a confident update and maybe director buys after the results are presented.